A Human Multi-Lineage Hepatic Organoid Model for Liver Fibrosis

Author:

Guan YuanORCID,Enejder Annika,Wang Meiyue,Fang Zhuoqing,Cui Lu,Chen Shih-Yu,Wang Jingxiao,Tan Yalun,Wu Manhong,Chen Xinyu,Johansson Patrik K.,Osman Issra,Kunimoto Koshi,Russo Pierre,Heilshorn Sarah C.,Peltz Gary

Abstract

AbstractBackgroundTo characterize fibrogenic mechanisms, genome engineering and a human hepatic organoid system was used to produce an in vitro model for human liver fibrosis.Methods and resultsHuman hepatic organoids that were engineered to express the most common causative mutation for Autosomal Recessive Polycystic Kidney Disease (ARPKD) developed the key features of ARPKD liver pathology (abnormal bile ducts and hepatic fibrosis) in only 21 days. Second harmonic generation microscopy confirmed that the ARPKD mutation increased collagen abundance and thick collagen fiber production in hepatic organoids; and we demonstrated that these changes mirrored that occurring in ARPKD liver tissue. Transcriptomic and other analyses indicated that the ARPKD mutation generates cholangiocytes with increased TGFβ-associated pathway activation, which are actively involved in collagen fiber generation. The abnormal cholangiocytes promote the expansion of collagen-producing myofibroblasts with markedly increased PDGFRβ protein expression and an activated STAT3 signaling pathway. Moreover, the transcriptome of ARPKD organoid myofibroblasts resembled that of myofibroblasts in liver tissue obtained from patients with commonly occurring acquired forms of liver fibrosis. The involvement of the PDGFRB pathway was confirmed by the anti-fibrotic effect observed when ARPKD organoids were treated with PDGFRB inhibitors.ConclusionsBesides providing mechanistic insight into the pathogenesis of congenital (and possibly acquired) forms of liver fibrosis, ARPKD organoids could also be used to test the anti-fibrotic efficacy of potential anti-fibrotic therapies.

Publisher

Cold Spring Harbor Laboratory

Reference100 articles.

1. Antifibrotic Therapies: Where Are We Now?;Semin Liver Dis,2016

2. Pathogenesis of Liver Fibrosis

3. Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease

4. Rock N , Kanavaki I , McLin VA. Congenital Hepatic Fibrosis, Caroli’s Disease, and Other Fibrocystic Liver Diseases. In: Guandalini S , Dhawan A , Branski D , eds. Textbook of Pediatric Gastroenterology, Hepatology and Nutrition. New York: Springer International Publishing, 2016:647–662.

5. Pathogenesis of biliary fibrosis

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3